Status: Recruiting
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Participants needed: 96
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Aug 19, 2026Locations: 94
Eligibility criteria
Participant must fulfill the 2013 American College of Rheumatology/ European Lea... [+5]
Any condition during Screening that could prevent a complete washout of medicati... [+8]